NASDAQ: TPST

Tempest Therapeutics Inc Stock Forecast, Predictions & Price Target

The consensus among 3 Wall Street analysts covering (NASDAQ: TPST) stock is to Strong Buy TPST stock.

Out of 3 analysts, 1 (33.33%) are recommending TPST as a Strong Buy, 2 (66.67%) are recommending TPST as a Buy, 0 (0%) are recommending TPST as a Hold, 0 (0%) are recommending TPST as a Sell, and 0 (0%) are recommending TPST as a Strong Sell.

If you're new to stock investing, here's how to buy Tempest Therapeutics stock.

(NASDAQ: TPST) Tempest Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.57%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.16%.

Tempest Therapeutics's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast TPST's revenue for 2027 to be $3,599,546,617, with the lowest TPST revenue forecast at $3,599,546,617, and the highest TPST revenue forecast at $3,599,546,617. On average, 2 Wall Street analysts forecast TPST's revenue for 2028 to be $6,495,051,210, with the lowest TPST revenue forecast at $296,263,547, and the highest TPST revenue forecast at $12,693,838,872.

In 2029, TPST is forecast to generate $1,278,926,458 in revenue, with the lowest revenue forecast at $1,278,926,458 and the highest revenue forecast at $1,278,926,458.

According to 3 Wall Street analysts that have issued a 1 year TPST price target, the average TPST price target is $25.00, with the highest TPST stock price forecast at $47.00 and the lowest TPST stock price forecast at $13.00.

On average, Wall Street analysts predict that Tempest Therapeutics's share price could reach $25.00 by Mar 20, 2025. The average Tempest Therapeutics stock price prediction forecasts a potential upside of 630.99% from the current TPST share price of $3.42.

(NASDAQ: TPST) forecast ROE is N/A, which is considered weak.